Cellectis vs Recursion Pharmaceuticals
Recursion Pharmaceuticals reported revenue of $75 million in fiscal 2025, about the same as Cellectis' $73 million in fiscal 2025. Cellectis' revenue grew 75.8% in its latest year, and Recursion Pharmaceuticals' grew 26.9%. Cellectis had an operating margin of -45.3%, against -867.9% at Recursion Pharmaceuticals. Free cash flow was −$42 million at Cellectis and −$378 million at Recursion Pharmaceuticals.
Side by side
| Cellectis | Recursion Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $73M | $75M |
| Revenue growth | 75.8% | 26.9% |
| Revenue growth a year, last 5 years | 7.4% | 79.6% |
| Gross margin | 100.0% | 5.0% |
| Operating margin | −45.3% | −867.9% |
| Net margin | −92.7% | −863.4% |
| Free cash flow | −$42M | −$378M |
| Free cash flow margin | −57.2% | −506.5% |
| Return on capital | — | −117.2% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 10.7% | 63.2% |
| Last close | $0.98 | $2.72 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | sold $6.9 million |
| Piotroski F-score | — | 4 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
CellectisRecursion Pharmaceuticals
Operating margin
Percent of revenue
CellectisRecursion Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CellectisRecursion Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Cellectis and Recursion Pharmaceuticals pages.